Pfizer Ends Pact With GlycoMimetics After SCD Failure

Rivipansel’s Sickle Cell Disease Trial Failure Triggered Pfizer’s Move

 
• By Sten Stovall
  
Contract_Termination
GlycoMimetics To Decide Whether Or Not To Continue Rivipansel Program • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip